Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 17:35:22 ON 14 MAY 2007
FILE 'REGISTRY' ENTERED AT 17:35:22 ON 14 MAY 2007

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.00	173.21

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.45	173.66

FILE 'REGISTRY' ENTERED AT 17:35:41 ON 14 MAY 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAY 2007 HIGHEST RN 934672-05-6
DICTIONARY FILE UPDATES: 13 MAY 2007 HIGHEST RN 934672-05-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-518405genB.str



chain nodes :

```
14  15  16  17  18  19
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13
chain bonds :
9-14  14-15  15-16  16-17  17-18  17-19
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  7-11  8-9  8-13  9-10  11-12  12-13
exact/norm bonds :
5-7  6-10  7-8  7-11  8-9  8-13  9-10  11-12  12-13  15-16  16-17  17-18  17-19
exact bonds :
9-14  14-15
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS



L4      STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l4 sss sam
SAMPLE SEARCH INITIATED 17:36:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      281 TO ITERATE

100.0% PROCESSED      281 ITERATIONS                          1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         4615 TO     6625
PROJECTED ANSWERS:               1 TO       80

L5            1 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 17:36:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     5428 TO ITERATE

100.0% PROCESSED     5428 ITERATIONS                         20 ANSWERS
```

SEARCH TIME: 00.00.01

L6 20 SEA SSS FUL L4

=> d scan

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-, 1,1-dimethylethyl ester, rel- (9CI)
MF C21 H29 N3 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):19

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, 2-ethoxy-N-[2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-, rel- (9CI)
MF C20 H27 N3 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, 2-methoxy-N-[2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-, rel- (9CI)
MF C19 H25 N3 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Urea, N-(1-methylethyl)-N'-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]- (9CI)
MF C20 H28 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Butanamide, 3-methyl-N-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]- (9CI)
MF C21 H29 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-[2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)ethyl]- (9CI)
MF C16 H19 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)ethyl]-, 1,1-dimethylethyl ester (9CI)
MF C19 H25 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanamide, 2-methoxy-N-[2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-, rel- (9CI)
MF C20 H27 N3 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-[2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-2-(phenylmethoxy)-, rel- (9CI)
MF C25 H29 N3 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Urea, N-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-

4-yl)propyl]-N'-(4-nitrophenyl)- (9CI)
MF C23 H25 N5 O5

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetic acid, [[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]amino]oxo-, ethyl ester (9CI)
MF C20 H25 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanamide, 2-methyl-N-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]- (9CI)
MF C20 H27 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [2-(8-cyano-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-4-yl)-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI)
MF C22 H29 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [2-[(3aR,4S,9bS)-8-cyano-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-4-yl]-2-methylpropyl]-, 1,1-dimethylethyl ester, rel- (9CI)
MF C22 H29 N3 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, 2-hydroxy-N-[2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-, rel- (9CI)
MF C18 H23 N3 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-[2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-2-phenoxy-, rel- (9CI)
MF C24 H27 N3 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Urea, N-(3-methylphenyl)-N'-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]- (9CI)
MF C24 H28 N4 O3

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanamide, 2,2-dimethyl-N-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]- (9CI)
MF C21 H29 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Acetamide, N-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]- (9CI)
MF C18 H23 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]-, 1,1-dimethylethyl ester (9CI)
MF C21 H29 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.90	347.56

FILE 'CAPLUS' ENTERED AT 17:38:25 ON 14 MAY 2007

FILE COVERS 1907 - 14 May 2007 VOL 146 ISS 21
FILE LAST UPDATED: 13 May 2007 (20070513/ED)

=> s l6
L7 3 L6

=> d l7 1-3 abs ibib hitstr

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I



II

AB The title nonsteroidal tetrahydroquinoline derivative with general formula of I [wherein R1 = NO2 or CN; n = 0 or 1; X = (un)substituted alkylene; Y = (un)substituted NHCO, NHSO2, NHCONH, or NHCSNH; R2 = (un)substituted Ph, heteroaryl, etc.] or pharmaceutically acceptable salts thereof are prepared as androgen receptor agonists, particularly on skeletal muscle tissues and bone tissues without showing any excessive effect on prostatic gland. For example, 4-aminobenzonitrile was reacted with cyclopentadiene and N-(2,2-dimethyl-3-oxopropyl)carbamic acid tert-Bu ester in MeCN in the presence of CF3CO2H, followed by hydrogenation, hydrolysis, and reacted with 4-trifluoromethoxybenzoic acid to give the amide II. The compds. I showed strong binding inhibitory activity against androgen receptor in rat. Formulations containing I as an active ingredient were also described.

ACCESSION NUMBER: 2004:120829 CAPLUS
DOCUMENT NUMBER: 140:181335
TITLE: Preparation of novel tetrahydroquinoline derivatives as androgen receptor agonists
INVENTOR(S): Miyakawa, Motonori; Oguro, Nao; Hanada, Keigo; Furuya, Kazuyuki; Yamamoto, Noriko
PATENT ASSIGNEE(S): Kaken Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004013104	A1	20040212	WO 2003-JP9815		20030801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003252333	A1	20040223	AU 2003-252333		20030801
EP 1541560	A1	20050615	EP 2003-766703		20030801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2005277660	A1	20051215	US 2005-522553		20050201
PRIORITY APPLN. INFO.:			JP 2002-225300	A	20020801
			WO 2003-JP9815	W	20030801

OTHER SOURCE(S): MARPAT 140:181335
IT 657407-79-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of novel tetrahydroquinoline derivs. as androgen receptor agonists)
RN 657407-79-9 CAPLUS
CN Carbamic acid, [2-[(3aR,4S,9bS)-8-cyano-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-4-yl]-2-methylpropyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
GI



AB The title nonsteroidal tetrahydroquinoline derivs. with general formula of I [wherein R1 = NO2 or CN; X = CH or O; m = 0 or 1; Y = (un)substituted alkylene; R2 = H, alkyl, cycloalkyl, or aralkyl; Z = (un)substituted alkyl, aryl, etc.] or pharmaceutically acceptable salts thereof are prepared as androgen receptor agonists. For example, the compound II was prepared in a three-step synthesis starting from 4-nitroaniline, cyclopentadiene, and tert-Bu N-(2,2,-dimethyl-3-oxopropyl)carbamate. II showed relative binding affinity of 1076 against androgen receptor in rat. Formulations containing I as an active ingredient were also described.

ACCESSION NUMBER: 2004:2862 CAPLUS
DOCUMENT NUMBER: 140:59527
TITLE: Preparation of bicyclic tetrahydroquinoline derivatives as androgen receptor agonists
INVENTOR(S): Miyakawa, Motonori; Sumita, Yuji; Furuya, Kazuyuki; Ichikawa, Kiyonoshin; Yamamoto, Noriko; Hanada, Keigo; Amano, Seiji; Nejishima, Hiroaki
PATENT ASSIGNEE(S): Kaken Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000816	A1	20031231	WO 2003-JP7799	20030619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003244313	A1	20040106	AU 2003-244313	20030619
EP 1520856	A1	20050406	EP 2003-760911	20030619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006128737	A1	20060615	US 2005-518405	20051118
PRIORITY APPLN. INFO.:			JP 2002-179088 A	20020619
			WO 2003-JP7799 W	20030619

OTHER SOURCE(S): MARPAT 140:59527

IT 637332-77-5P 637332-89-9P 637332-91-3P
637333-15-4P 637333-16-5P 637333-17-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of bicyclic tetrahydroquinoline derivs. as androgen receptor agonists)

RN 637332-77-5 CAPLUS

CN Acetamide, 2-methoxy-N-[2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 637332-89-9 CAPLUS
CN Acetamide, N-[2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-2-phenoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 637332-91-3 CAPLUS
CN Acetamide, N-[2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-2-(phenylmethoxy)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 637333-15-4 CAPLUS
CN Acetamide, 2-ethoxy-N-[2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 637333-16-5 CAPLUS
CN Acetamide, 2-hydroxy-N-[2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 637333-17-6 CAPLUS

CN Propanamide, 2-methoxy-N-[2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 637334-21-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of bicyclic tetrahydroquinoline derivs. as androgen receptor agonists)

RN 637334-21-5 CAPLUS

CN Carbamic acid, [2-methyl-2-[(3aR,4S,9bS)-3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

GI



I



II

AB Title compds. [I; R1 = 3-NO2, 3-CN, 2-NO2, 3-CH3S, 3-CH3SO, 3-CH3SO2,; R2 = H, 1-OH; R3 = TBDPS, H, CH2OCH3, CH3, CH2CH3, 4-FC6H4, COCH3, (CH3)2CH; n = 0, 1; X = CH, CH2, O; dotted bond = single, double; Y = (CH3)2C, CH2CH2, Z = NHCONH, O, NHCSNH, SO, SO2 S, NHCO] or salts thereof, having a specific and strong binding affinity for AR and exhibiting AR agonism or antagonism; and drug compns. containing the derivs. or the salts, are prepared Thus, the title compound II was prepared and biol. tested.

ACCESSION NUMBER: 2001:283930 CAPLUS
DOCUMENT NUMBER: 134:295752
TITLE: Preparation of tetrahydroquinoline derivatives as androgen receptor regulators
INVENTOR(S): Hanada, Keigo; Furuya, Kazuyuki; Inoguchi, Kiyoshi; Miyakawa, Motonori; Nagata, Naoya
PATENT ASSIGNEE(S): Kaken Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027086	A1	20010419	WO 2000-JP7007	20001006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2387201	A1	20010419	CA 2000-2387201	20001006
AU 200075589	A	20010423	AU 2000-75589	20001006
EP 1221439	A1	20020710	EP 2000-964738	20001006
EP 1221439	B1	20070103		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 350036	T	20070115	AT 2000-964738	20001006

US 7037919 B1 20060502 US 2002-110636 20020814
PRIORITY APPLN. INFO.: JP 1999-292021 A 19991014
WO 2000-JP7007 W 20001006

OTHER SOURCE(S): MARPAT 134:295752

IT 334875-94-4P 334875-96-6P 334876-19-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of tetrahydroquinoline derivs. as androgen receptor regulators)

RN 334875-94-4 CAPLUS
CN Acetamide, N-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]- (9CI) (CA INDEX NAME)



RN 334875-96-6 CAPLUS
CN Propanamide, 2-methyl-N-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]- (9CI) (CA INDEX NAME)



RN 334876-19-6 CAPLUS
CN Urea, N-(1-methylethyl)-N'-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]- (9CI) (CA INDEX NAME)



IT 334875-40-0P 334875-42-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydroquinoline derivs. as androgen receptor regulators)

RN 334875-40-0 CAPLUS
CN Carbamic acid, [2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 334875-42-2 CAPLUS
CN Carbamic acid, [2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 334875-44-4P 334875-92-2P 334875-98-8P
334876-00-5P 334876-07-2P 334876-21-0P
334876-23-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of tetrahydroquinoline derivs. as androgen receptor regulators)

RN 334875-44-4 CAPLUS
CN Carbamic acid, [2-(8-cyano-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-4-yl)-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 334875-92-2 CAPLUS
CN Acetamide, N-[2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 334875-98-8 CAPLUS
CN Butanamide, 3-methyl-N-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]- (9CI) (CA INDEX NAME)



RN 334876-00-5 CAPLUS
CN Propanamide, 2,2-dimethyl-N-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]- (9CI) (CA INDEX NAME)



RN 334876-07-2 CAPLUS
CN Acetic acid, [[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 334876-21-0 CAPLUS
CN Urea, N-(3-methylphenyl)-N'-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 334876-23-2 CAPLUS
CN Urea, N-[2-methyl-2-(3a,4,5,9b-tetrahydro-8-nitro-3H-cyclopenta[c]quinolin-4-yl)propyl]-N'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.57	367.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 17:43:10 ON 14 MAY 2007

DICTIONARY OF BIOCHEMISTRY AND MOLECULAR BIOLOGY

Second Edition

J. STENESH

Professor of Chemistry
Western Michigan University

WILEY

A WILEY-INTERSCIENCE PUBLICATION

JOHN WILEY & SONS

New York / Chichester / Brisbane / Toronto / Singapore

Library of Congress Cataloging in Publication Data:

Stenesh, J., 1927–
Dictionary of biochemistry and molecular biology / J. Stenesh. — 2nd ed.
p. cm.
Rev. ed. of: Dictionary of biochemistry, 1975.
"A Wiley-Interscience publication."
Bibliography: p.
ISBN 0-471-84089-0
1. Biochemistry—Dictionaries. 2. Molecular biology—
—Dictionaries. I. Stenesh, J., 1927– Dictionary of biochemistry.
II. Title.
QP512.S73 1989
574.19'2'0321—dc19 88-38561
CIP

Printed in the United States of America

10 9 8 7 6 5 4

their activities. *Abbr* PN.

protecting group A chemical group that is reacted with, and bound to, a functional group in a molecule to prevent the functional group from participating in subsequent reactions of the molecule.

protective antigen An antigen that is derived from a pathogenic microorganism and that, when injected into an animal, will produce an immune response that will provide protection for the animal against infection by that microorganism.

protective colloid A colloid that is added to a food to prevent the separation of components in that food.

protective immunity Immunity that is produced in an organism to protect the latter against possible exposure to a pathogen or other harmful agent.

proteid Obsolete term for either protein or conjugated protein.

protein A high molecular weight polypeptide of L-amino acids that is synthesized by living cells. Proteins are biopolymers with a wide range of molecular weights, structural complexity, and functional properties. Proteins are variously classified on the basis of their (a) solubility (albumins, globulins, scleroproteins, etc.); (b) function (transport proteins, storage proteins, contractile proteins, enzymes, hormones, antibodies, etc.); (c) shape (globular proteins and fibrous proteins); (d) composition (simple proteins, conjugated proteins, and derived proteins).

protein A A cell wall protein of some strains of *Staphylococcus aureus* that combines with most human immunoglobulin molecules of the IgG type.

proteinaceous Consisting in part, or entirely, of protein.

proteinase 1. PROTEOLYTIC ENZYME. 2. A protease that shows specificity for intact (native) proteins.

protein biosynthesis *See* protein synthesis.

protein blotting A method for identifying and characterizing proteins in complex mixtures. Involves separating the protein mixture into its components by some gel electrophoretic technique, most commonly by SDS–PAGE. After electrophoresis, the proteins are eluted from the gel by a second electrophoresis, diffusion, or convection, and are adsorbed onto an immobilized matrix (nitrocellulose membrane filters, nylon-based membranes, diazotized paper, etc.) such that the original electrophoretic separation pattern is maintained. The immobilizing matrix, or blot, is reacted with an appropriate probe (antibody, lectin, etc.) so that the protein of interest can be detected.

protein-bound iodine The iodine in the blood that is conjugated to protein and that is a measure of the concentration of circulating thyroid hormone. *Abbr* PBI.

protein C FACTOR XIV. *See also* C-protein.

protein–calorie malnutrition The combined deficiency of both calories and proteins as it occurs during famine; a combination of the conditions of marasmus and kwashiorkor.

protein coat The protein shell that surrounds the nucleic acid of a virus. *See also* capsid.

protein conformation *See* chain conformation; primary structure; secondary structure; tertiary structure; quaternary structure; super secondary structure; domain.

protein domain *See* domain.

protein efficiency ratio A measure of the nutritive value of a protein defined as the gain in weight (in grams) per gram of protein consumed; eggs are considered to have a maximum protein efficiency ratio of about 4.4.

protein efficiency ratio method A method for determining the nutritive value of a protein by measuring the gain in weight of young rats that are fed a diet containing 10% of the particular protein. *Abbr* PER method.

protein engineering The design and construction of new proteins or enzymes, which have novel properties, by the methods of recombinant DNA technology.

protein error The change in the relative amounts of the undissociated and dissociated forms of an indicator that is brought about by the binding of one of these forms to a protein. The change in the relative amounts of indicator forms leads to a change in color; such a color change forms the basis of the albustix test.

protein evolution The molecular evolution of proteins. *See also* chemical evolution.

protein export The transport of a protein out of a cell; the secretion of an extracellular protein.

protein factor The factor 6.25 that, when multiplied by the weight of nitrogen (in grams) derived from a sample containing protein, gives the approximate weight (in grams) of the protein in the sample.

protein folding The processes involved in the conversion of an ensemble of newly synthesized (or denatured) polypeptide chain conformations to the unique, three-dimensional conformation of the native protein.

protein fractionation The separation of a mixture of different proteins for the purpose of isolating one particular type of protein; requires the use of one or more physical–chemical techniques such as precipitation, chromatography, centrifugation, or electrophoresis.

About Entrez
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI
Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

Search	Most Recent Queries	Time	Result
#12	Search **#8 and $quinoline**	18:44:14	2
#13	Search **#8 and tetrahydoquinoline**	18:43:55	0
#8	Search **androgen and receptor and ("hypogonadism" or "sexual dysfunction" or "sex differentiation" or puberty or mastopathy or endometriosis)**	18:43:03	1325
#9	Search **#8 and agonist**	18:42:08	45
#7	Search **androgen and receptor and ("hypogonadism" or "sexual dysfunction" or sex differentiation" or puberty or mastopathy or endometriosis)**	18:37:20	1325
#6	Search **androgen and receptor**	18:33:36	12210
#5	Search **AR and agonism**	18:32:35	58
#4	Search **RA and agonism**	18:31:22	8
#3	Search **H3 and receptor and (diversity or complexities or controversial or uncertainty)**	12:09:33	16
#2	Search **H3 and receptor and (diversity or complexity or controversial or uncertainty)**	12:07:55	23
#1	Search **H3 and receptor**	12:05:49	1570

Clear History

Items 1 - 2 of 2 One page.

1: Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Lopez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A. Related Articles, Links

An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate.
Endocrinology. 2007 Jan;148(1):363-73. Epub 2006 Oct 5.
PMID: 17023534 [PubMed - indexed for MEDLINE]

2: Zhi L, Tegley CM, Pio B, Edwards JP, Motamedi M, Jones TK, Marschke KB, Mais DE, Risek B, Schrader WT. Related Articles, Links

5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
J Med Chem. 2003 Sep 11;46(19):4104-12.
PMID: 12954062 [PubMed - indexed for MEDLINE]